All In Biotech

Drug Trial Radar · NCT06520488

A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors

Phase IB/II Clinical Study of the Safety, Tolerability and Efficacy of HRS-4642 in Combination With Anti-tumor Agents in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

118

Planned (sponsor's estimate)

Start

Aug 9, 2024

Primary completion

Mar 2027

Study completion Jul 2027

Sponsor

Sponsor type
Industry
First posted
Jul 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and preliminary efficacy of HRS-4642 in combination with antineoplastic agents in subjects with advanced solid tumors with KRAS G12D mutations, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).

Conditions

  • Advanced Solid Tumors

Interventions

  • HRS-4642Drug

    Treatment group Part I: HRS-4642 combined with SHR-A1921 Treatment group Part II: HRS-4642 combined with SHR-A1904 Treatment group Part II: HRS-4642 combined with AG

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: (IB Period):DLTsTime frame: Within 28 days of the first dose
  2. Stage 1: (IB Period): adverse events (AEs)Time frame: Within 28 days of the first dos,About 1 year
  3. Phase II: (Phase II):investigator-assessed ORRTime frame: Assessed every 6 weeks,About 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Renji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.